Return to the catalog
BPC-157
PopularIn Stock5mg vial

BPC-157

Peptide fragment studied for stomach and digestive health, and the repair of tendons and other connective tissue.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 500.00
5+ vials — save 24%R 380.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

BPC-157 is a laboratory-made peptide made up of 15 amino acids and based on a protective protein found in the stomach. Researchers study how it may support the stomach lining, blood-vessel signalling, and the repair of tendons, ligaments, and other connective tissue. Most of this research has been carried out in animal and laboratory models.

Why researchers reach for BPC-157

Connective tissue focus

Widely cited in tendon, ligament and muscle-injury rodent models.

GI barrier studies

Referenced for gastric and intestinal mucosal integrity work.

Angiogenic signaling

Preclinical data suggest VEGFR2 pathway involvement.

Key features

  • ≥99% HPLC purity
  • Stable pentadecapeptide sequence
  • Mass-spec confirmed identity
  • Cold-chain shipped

How it works

Growth factor cross-talk

Modulates VEGF, FGF and EGR-1 signaling in vitro.

Nitric oxide pathway

Interacts with NO system in vascular endothelial studies.

Cytoprotection

Reduces markers of oxidative stress in animal GI models.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 2.5 mg/mL (2500 mcg/mL)
Reported research range200–500 mcg/dayReference only

Tracking this compound? Registered researchers can log active BPC-157 protocols in their private Research Log.

Timing in research protocols

No human timing data; short half-life in animal pharmacokinetics.

  • No human trials have been published; a 2025 pharmaceuticals review notes the absence of comprehensive clinical studies.
  • Rat and dog pharmacokinetics show an elimination half-life under 30 minutes, with intramuscular bioavailability around 14–19% in rats and 45–51% in dogs.
  • Frequent, split daily dosing seen in circulating protocols is an inference from that short half-life, not a tested schedule.
  • No evidence-based time of day, meal relationship or cycle length exists.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
GEPPPGKPADDAGLV
Molecular weight
1419.5 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
5 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on BPC-157. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#recovery#gastroprotection#tendon#angiogenesis

Cart (0)

Your cart is empty